



HARMONIZED SYSTEM
COMMITTEE

-
29th Session
-

NC0570E1
(+ Annex)

O. Eng.

Brussels, 16 April 2002.

CLASSIFICATION OF NEW INN PRODUCTS (WHO LISTS 84 AND 85)

(Item V.3 on Agenda)

Reference document :

NS0060E2, Annex A/2 (SSC/17 – Report)

I. BACKGROUND

1. At the 17th Session of the Scientific Sub-Committee, the Director reminded the Sub-Committee that INN Lists 84 and 85 had been sent to administrations on 10 December 2001 and requested delegates to submit comments by mid-March 2002 at the latest so that the Secretariat could prepare a working document for the Harmonized System Committee's 29th Session (see Annex A/2 to Doc. NS0060E2).
2. Since the next (18th) Session of the Scientific Sub-Committee will not be held before January 2003, it was the Secretariat's intention to submit the agreed classifications to the next (29th) Session of the Harmonized System Committee for decision, after obtaining the approval of the Chairman of the Scientific Sub-Committee.

II. SECRETARIAT ACTION

3. As of the end of March 2002, the Secretariat had received comments from the EC, Canada and Sri Lanka. The Secretariat has reproduced the products listed in WHO Lists 84 and 85 in the Annex hereto and reflected the comments received from the above administrations. INNs on which there was consensus on classification are indicated in **bold** type and identified as "Agreed classification" in the Remarks column. The Annex also incorporates the list of products for which there were doubts or different views on classification. The proposed classifications in these cases have been placed in square brackets.

Note : Shaded parts will be removed when documents are placed on the WCO documentation database available to the public.

File No. 2549

4. The proposed classifications, as set out in the Annex hereto, were forwarded to the Chairman of the Scientific Sub-Committee for approval. They have also been sent to the delegates to the Scientific Sub-Committee with a view to them conveying their comments, if any, to the Harmonized System Committee.
5. On 15 April 2002, the Secretariat received a reply from the Chairman of the Scientific Sub-Committee, conveying his approval of the "agreed classifications" indicated in **bold** type in the Annex. He also indicated that other products where classifications were doubtful, should be discussed at the next Scientific Sub-Committee meeting in 2003.

III. SECRETARIAT COMMENTS

6. Since the Chairman of the Scientific Sub-Committee and 18 Contracting Parties (including the 15 Member states of the European Union) have given their approval to the "agreed classifications", the Secretariat would invite the Committee to accept the proposed classifications for these **96 INN products** (48 from each INN List) indicated in **bold** type in the Annex to this document.
7. The classification of the remaining INN products (16 cases from List 84 and 21 cases from List 85 for which the proposed classifications have been placed in square brackets in the Annex hereto) will be submitted to the next (18th) Session of the Scientific Sub-Committee in January 2003.

IV. CONCLUSION

8. The Committee is invited to accept the classifications of 96 INN products as indicated in **bold** type in the Annex.

* * *

List of new INN products (WHO List 84)

INN	Proposed classification	Remarks
abrineurin	[2934.99] [2937.19]	
carglumic acid	2924.19	Agreed classification
lidadronic acid	2931.00	Agreed classification
agalsidase alfa	3507.90	Agreed classification
agalsidase beta	3507.90	Agreed classification
alefacept	[3002.10]	
alfatradiol	[2906.29] [2907.29]	
aprepitant	2934.99	Agreed classification
aviscumine	[2933.99] [3002.90]	
balaglitazone	2934.10	Agreed classification
bimosiamose	2940.00	Agreed classification
brostallicin	2933.99	Agreed classification
diflomotecan	[2934.99] [2939.99]	
edotreotide	2934.99	Agreed classification
edronocaine	2922.19	Agreed classification
eflucimibe	2930.90	Agreed classification
eganoprost	2937.50	Agreed classification
emodepside	2934.99	Agreed classification
erlizumab	3002.10	Agreed classification
ertapenem	2941.90	Agreed classification
etoricoxib	2933.39	Agreed classification
eufausease	3507.90	Agreed classification
farglitazar	2934.99	Agreed classification
fesoterodine	[2922.29] [2922.50]	
gavilimomab	3002.10	Agreed classification
gemopatrilat	2933.79	Agreed classification
Imatinib	2933.59	Agreed classification
insulin glulisine	[2937.12] [2937.19]	
lemalesomab	3002.10	Agreed classification
litomeglovir	2935.00	Agreed classification
micafungin	[2941.90] [2934.99]	
mozenavir	2933.99	Agreed classification
navuridine	2934.99	Agreed classification

INN	Proposed classification	Remarks
neramexane	2921.30	Agreed classification
nolomirole	2922.29	Agreed classification
omaciclovir	2933.59	Agreed classification
omalizumab	3002.10	Agreed classification
peginterferon alfa-2a	[3907.20] [3002.10] [3504.00]	
peginterferon alfa-2b	[3907.20] [3002.10] [3504.00]	
pipendoxifene	2933.39	Agreed classification
pitrakinra	[2934.99] [3002.10]	
pradofloxacin	2933.49	Agreed classification
reglitazar	2934.99	Agreed classification
rivoglitazone	2934.10	Agreed classification
sabiporide	2933.59	Agreed classification
safinamide	2924.29	Agreed classification
sibenadet	[2934.10] [2934.20]	
soblidotin	[2933.99] [2941.90]	
soneclosan	2909.50	Agreed classification
sumanirole	[2933.99] [2933.99]	
taplitumomab paptox	3002.10	Agreed classification
tezacitabine	2934.99	Agreed classification
tidembersat	2932.99	Agreed classification
tilmacoxib	2935.00	Agreed classification
tipifarnib	[2933.49] [2933.79]	
tomeglovir	2935.00	Agreed classification
traxoprodil	[2933.39] [2933.59]	
tridolgosir	2933.99	Agreed classification
valomaciclovir	2933.59	Agreed classification
vatalanib	2933.39	Agreed classification
visilizumab	3002.10	Agreed classification
ximelagatran	2933.99	Agreed classification
zelandopam	2933.49	Agreed classification
ziralumab	3002.10	Agreed classification

List of new INN products (WHO List 85)

INN	Proposed classification	Remarks
gadocoletic acid	2846.90	Agreed classification
afeletecan	2939.99	Agreed classification
alfimeprase	3507.90	Agreed classification
alicaforsen	[2934.99]	
alilusem	2933.49	Agreed classification
ambrisentan	2933.59	Agreed classification
amdoxovir	2934.99	Agreed classification
amelubant	[29.37] [2925.20]	
amotosalen	2932.29	Agreed classification
bimatoprost	[2924.29] [2937.50] [2937.90]	
caldaret	2933.59	Agreed classification
cipralisant	2933.29	Agreed classification
dalbavancin	2941.90	Agreed classification
darbepoetin alfa	[2934.99] [3002.10]	
drotrecogin alfa	[3002.10]	
ecalcidene	2933.39	Agreed classification
efalizumab	3002.10	Agreed classification
enfuvirtide	[2933.29] [2933.99]	
epafipase	[2935.90] [3504.90] [3507.90]	
epoetin delta	[2934.90] [3002.10]	
erlosamide	2924.29	Agreed classification
erlotinib	2933.59	Agreed classification
febuxostat	2934.10	Agreed classification
felopreentan	2933.59	Agreed classification
finafloxacin	2934.99	Agreed classification
gadomelitol	2846.90	Agreed classification
garnocestim	[2934.99] [3002.10]	
gefitinib	2934.99	Agreed classification
ingliferib	2933.99	Agreed classification
ipravacaine	2933.39	Agreed classification
iseganan	2934.99	Agreed classification

INN	Proposed classification	Remarks
labetuzumab	3002.10	Agreed classification
laniquidar	2933.49	Agreed classification
lapisteride	[2924.29] [2933.79]	
laquinimod	2933.79	Agreed classification
laronidase	3507.90	Agreed classification
lirimilast	2932.99	Agreed classification
livaraparin calcium	[3001.90] [3913.90]	
manifaxine	2934.99	Agreed classification
miglustat	2933.39	Agreed classification
miriplatin	2843.90	Agreed classification
mirostipen	[2934.99] [3002.10]	
mureletecan	[2939.99] [3908.90]	
nasaruplase beta	3507.90	Agreed classification
netoglitazone	2934.10	Agreed classification
ospemifene	2909.49	Agreed classification
pegfilgrastim	[3002.10] [3907.20]	
pexelizumab	3002.10	Agreed classification
pralnacasan	[2933.49] [2934.99] [3507.90]	
pratosartan	[2933.99] [29.37]	
ragaglitazar	2934.99	Agreed classification
reminertant	[2933.49] [29.37]	
reslizumab	3002.10	Agreed classification
ruboxistaurin	2934.99	Agreed classification
semaxanib	2933.79	Agreed classification
senazodan	2933.39	Agreed classification
silodosin	2933.99	Agreed classification
solifenacin	2933.49	Agreed classification
tadalafil	2934.99	Agreed classification
tafluposide	2940.00	Agreed classification
telbermin	[2934.99] [29.37]	
tenivastatin	[2918.29] [2918.19]	
tesaglitazar	2918.90	Agreed classification

INN	Proposed classification	Remarks
tofimilast	2934.99	Agreed classification
xidecaflur	2922.19	Agreed classification
zanapezil	2933.39	Agreed classification
zonampanel	[2933.29] [2933.59]	
zoniporide	2933.49	Agreed classification
zoticasone	[2937.22] [2937.29]	
